A 16‐month‐long experience of <scp>COVID</scp>‐19 in allogeneic haematopoietic stem cell transplantation recipients: An <scp>SFGM‐TC</scp> multicentre cohort study-Reference-Cited by-同舟云学术

A 16‐month‐long experience of COVID‐19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM‐TC multicentre cohort study

Published:2023-03-15 Issue:6 Volume:201 Page:1066-1071
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Xhaard Aliénor¹^ORCID,Xhaard Constance²,Rubio Marie‐Therese³,Berceanu Ana⁴,Botella‐Garcia Carmen⁵,Coman Tereza⁶,Tavernier Emmanuelle⁷,Labussière‐Wallet Hélène⁸,Chevallier Patrice⁹^ORCID,Legrand Faezeh¹⁰,Thiebaut Anne¹¹,Menard Anne‐Lise¹²,Paillard Catherine¹³,Chantepie Sylvain¹⁴,Robin Marie¹,Nguyen Stephanie¹⁵

Affiliation:

1. Service d'hématologie‐Greffe, Hôpital Saint‐Louis, Assistance Publique‐Hôpitaux de Paris Université Paris Diderot Paris France

2. INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM 1116, CHRU de Nancy, FCRIN INI‐CRCT Université de Lorraine Nancy France

3. Service d'hématologie Hôpital Brabois, CHRU Nancy et CNRS UMR 7563, Biopôle de l'Université de Lorraine Vandoeuvre les Nancy France

4. Service d'hématologie CHU Jean Minjoz Besançon France

5. Service d'hématologie CHU Bordeaux Bordeaux France

6. Service d'hématologie Institut Gustave Roussy Villejuif France

7. Département d'hématologie Clinique et de Thérapie Cellulaire CHU Saint‐Etienne Saint‐Etienne France

8. Service d'hématologie Hôpital Lyon Sud Pierre Bénite Cedex France

9. Service d'hématologie CHU Nantes France

10. Département d'hématologie Institut Paoli‐Calmettes Marseille France

11. Service d'hématologie CHU Grenoble Grenoble France

12. Service d'hématologie CHU Rouen Rouen France

13. Service d'hématologie pédiatrique CHRU Strasbourg Strasbourg France

14. Service d'hématologie CHU Caen Caen France

15. Service d'hématologie Sorbonne Université Groupe Hospitalier Pitié‐Salpêtrière Paris France

Abstract

SummaryThis 16‐month‐long multicentre retrospective study of 225 allogeneic haematopoietic stem cell transplantation (alloHSCT) recipients with COVID‐19 examines risk factors for severity and mortality, describing the successive waves of infections (from March to June 2020 and from August 2020 to June 2021). We confirm the negative role of low respiratory tract disease and immunosuppressive treatment. We highlight significantly lower percentages of severe forms and COVID‐19‐related mortality during the second wave. Monthly comparative evolution of cases in alloHSCT recipients and in the French population shows a higher number of cases in alloHSCT recipients during the first wave and a decrease from February 2021.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18754

Reference10 articles.

1. Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort study

2. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

3. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

4. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

5. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant;Human Vaccines & Immunotherapeutics;2024-07-08

2. Characteristics of Coronavirus Disease in Allogeneic Hematopoietic Stem Cell Transplantation During the Omicron Wave: A Single-Center Study;Open Forum Infectious Diseases;2024-01-23

3. Impact de la pandémie Covid-19 sur l’activité nationale et les risques afférents à la greffe de cellules souches hématopoïétiques - Une étude rétrospective conjointe de la Société francophone de greffe de moelle et de thérapie cellulaire et de l’Agence de la biomédecine, et une revue de la littérature;Hématologie;2023-07-01